Biologics / Biotechnology

#Academic #Analysis #Animal models #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Immunology #Lead discovery #Molecular medicine #Pathology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

New Mechanisms and Expanded Indications for Biologic Therapies

New Mechanisms and Expanded Indications for Biologic Therapies: a perspective on immunology research and development By Dr Susan B. Dillon Over the past decade, the introduction of biologic therapies has had a profound impact for millions of patients with immune-mediated arthritides, inflammatory bowel diseases and plaque psoriasis. Today, five anti-Tumor… Read More

#Archive

Electronic laboratory notebook (ELN)
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Chemical engineering #Chemistry #Computational chemistry #Drug development #High Content Screening #Mass spectrometry / NMR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Target validation

Enterprise ELNs as a Foundation for Preclinical Drug Development

Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Genomics #Lead discovery #Protein chemistry / Proteomics #RNA #Screening

Leveraging Research Informatics to Accelerate Drug Discovery

Leveraging Research Informatics to Accelerate Drug Discovery By Dr Anirban Ghosh and Siddharth Sawhney Research informatics has a vital array of tools which can advance the speed and success rate of drug discovery. This article discusses that if pharma companies want to benefit from these tools and are serious about… Read More

#Archive

#Academic #Analytical chemistry #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Gene therapy #High Content Screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Patent Law #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Singapore Strengthens Position as Leading Site for Biopharmaceutical R&D

Singapore Strengthens Position as Leading Site for Biopharmaceutical R&D By Kian-Teik Beh Globally, pharmaceutical and biotech companies are confronted by an impending patent cliff, while being challenged with declining research and development (R&D) productivity and the need to integrate multidisciplinary scientific capabilities.       Against this backdrop, Asia presents… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Gene therapy #High Content Screening #Imaging #Immunology #Lead discovery #Regulatory #RNA #Stem cells

Stem Cell Therapies: Assessing the commercial opportunity

Share Share Tweet Email Stem Cell Therapies: Assessing the commercial opportunity Stem Cell Therapies: Assessing the commercial opportunity By Su Webber, Andrew Millest and Mark Williams Restructuring and reorganisation is routine and relentless in the pharmaceutical industry, with a future focus essential for effective strategic decision making. In recent years,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Drug development #Drug discovery #Drug targets #Lead discovery #Regulatory #RNA #Translational #Translational chemistry

How Pharma Companies Manage in a Tough Financial Climate

How Pharma Companies Manage in a Tough Financial Climate By Paul Branthwaite Maintaining knowledge and experience internally is a challenge in today's financial climate, in SMEs and in big pharma. This article provides some tips on how companies can maintain their best staff or find reliable alternative options, especially at… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Clinical specialities #Clinical trials #Gene therapy #Pathology #Regulatory #RNA #Therapeutics #Toxicology

A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema

A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema By Dr Edward E. Berger Emphysema is a progressive, debilitating disease that affects approximately 4.1 million people in the United States or roughly 1% of the US population. The disease is characterised by destruction of lung tissue as a result of inflammation… Read More

#Archive

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Oncology #Pathology #Preclinical #RNA #Target validation #Toxicology #Translational #Translational chemistry

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics By Dr William E. Fogler Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #Sequencing #Stem cells #System biology #Systems biology

21st Century Vaccines – A Development Renaissance

21st Century Vaccines - A Development Renaissance By Dr Jeff Stoddard, Charles Drucker and Dr Nigel Brown Human beings have benefited from vaccines for more than two centuries. From eradicating some of the deadliest diseases to nearly eliminating a host of others, including polio, measles, mumps and tetanus - vaccines… Read More

#Archive

#Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Orphan drugs #PCR #Pharmacology #Regulatory #Screening #Stem cells #System biology #Systems biology

GPCRs – New Strategies for an Old Target Class

William Downey and Dr Shauna Farr-Jones GPCRs are the most studied drug target class and have a proven record as valuable drug targets, with 40-50% of marketed drugs being modulators of GPCR function. Despite the intense effort focused on these targets by the pharmaceutical industry over many years, numerous challenges… Read More

#Archive

#Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Target validation #Therapeutics #Toxicology

Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens

Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models for testing… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biobanking #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Patent Law #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Automated Biobanking – The next big step for biorespositories

Automated Biobanking - The next big step for biorespositories By Dr John Comley As a significant proportion of the many newly established national, regional and disease-specific biobanks or biorespositories contemplate how they will enable enhanced sample integrity, tracking and audit trail, there has never been a more opportune time to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Lead discovery #Molecular medicine #Pharmokinetics #Regulatory #RNA #Stem cells #System biology #Therapeutics #Toxicology

Monoclonals – The billion dollar molecules of the future

Monoclonals - The billion dollar molecules of the future By Dr Martin Wiles and Patrik Andreassen In 1975, two British scientists thought of creating a mouse antibody that could be replicated or 'cloned' to produce identical copies. Identical copies with identical modes of action had the potential to be a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Pharmacogenomics #Pharmacology #Regulatory #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The Biomedical Ecosystem Delivering Better Health and Prosperity

The Biomedical Ecosystem Delivering Better Health and Prosperity By Dr Peter B. Corr The overall message is simple: biomedical innovation and the public policies and new technologies that sustain and advance innovation are crucial to the future of biomedical science and the health and well being of our society. In… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Lead discovery #Medicinal chemistry #Molecular medicine #Protein chemistry / Proteomics #Regulatory #RNA #Therapeutics

How a new compliance agenda is changing the face of the drug discovery industry

How a new compliance agenda is changing the face of the drug discovery industry By Dr Doug Dean and Frances Bruttin Safe and effective drug products for the 21st century can be developed if, and only if, firms understand the mechanism of action of their products, and they are able… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Pharmacology #Pharmokinetics #Regulatory #RNA #Screening #Target validation #Toxicology

Applications of liquid chromatography mass spectrometry

Applications of liquid chromatography mass spectrometry By Dr David Kwok Applications of liquid chromatography mass spectrometry in accelerating the pace of lead-drug candidate selection and pre-clinical development. This review discusses how the application and benefits of using LC/MS and LC/MS/MS assays in conjunction with in vivo and in vitro study… Read More

#Archive